Artrya Limited (AU:AYA) has released an update.
Artrya Limited has made significant strides by submitting a 510(k) application to the US FDA for its Salix® Coronary Anatomy software, aiming to penetrate the US market. The company successfully integrated its software into Tanner Health System, marking a key step in its pre-FDA clearance process, and reported its first revenues from processing over 500 CCTA scans. With $6.5 million in cash as of September 2024, Artrya continues to focus on cost management and strategic growth in the cardiovascular technology sector.
For further insights into AU:AYA stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
